ImmuPharma plots reversal
Drug developer ImmuPharma, which is focusing its efforts on converting small peptides into clinically viable compounds, hopes to launch on AIM on Friday – after raising £2.2 million from investors with the aid of broker KBC Peel Hunt.
News